Literature DB >> 6131529

[Comparison of treatment with griseofulvin, beta blockers and calcitonin in 55 cases of post-traumatic algoneurodystrophies].

L Friez, G Pere, P Breuillard, S Meignan.   

Abstract

A comparative study of three treatments of reflex sympathetic dystrophy (selected at random) was carried out on 55 cases : 20 patients were treated with calcitonin, 19 with beta-blocking agents, and 16 with griseofulvin. The delay in drug effect seems similar for the 3 drugs but griseofulvin is associated with a greater failure rate. The beta-blocking agents and calcitonin gave comparable results. beta-Blocking agents appear to obtain better results than other 2 treatments in patients with a psychological component to their disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6131529

Source DB:  PubMed          Journal:  Rev Rhum Mal Osteoartic        ISSN: 0035-2659


  5 in total

1.  Regional intravenous guanethidine blocks in algodystrophy.

Authors:  F Eulry; D Lechevalier; B Pats; C Alliaume; P Crozes; P Vasseur; G Coutant; D Felten; S Pattin
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

2.  Reflex sympathetic dystrophy: an underreported syndrome in children?

Authors:  R A Lemahieu; C Van Laere; L A Verbruggen
Journal:  Eur J Pediatr       Date:  1988-01       Impact factor: 3.183

3.  Complex Regional Pain Syndrome.

Authors:  Ok Yung Chung; Stephen P. Bruehl
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

4.  Scintigraphic evaluation of reflex sympathetic dystrophy: comparative study of the course of the disease under two therapeutic regimens.

Authors:  H Rico; E Merono; F Gomez-Castresana; J Torrubiano; D Espinos; P Diaz
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

Review 5.  A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms.

Authors:  Cyrille B Confavreux; Robert L Levine; Gerard Karsenty
Journal:  Mol Cell Endocrinol       Date:  2009-04-17       Impact factor: 4.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.